Name: Tozadenant
Price: 277.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    Tozadenant (SYN115) is an orally active, selective adenosine A2A receptor antagonist. In animal models of Parkinson’s disease, tozadenant improves motor neuron function. Tozadenant (60 mg twice daily) was not associated with a signi cant reduction in o -time, and tozadenant (240 mg twice daily) was associated with an increased rate of discontinuation because of adverse events (17 of 84 patients [20%]). Tozadenant at dose of 120 or 180 mg twice daily was e ective at reducing o -time and was generally well tolerated. Further investigation of tozadenant treatment in phase 3 trials is guaranteed. Perfusion MRI showed that tozadenant induced highly signi cant suppressed in regional cerebral blood ow, with the most important decreases occurring in bilateral thalami.
- Properties
  - Categories
    
    Adenosine 2a receptor antagonist, novel and selective
    
    Alternative Name
    
    SYN-115;SYN115;SYN 115; 4-hydroxy-N-(4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-yl)-4-methylpiperidine-1-carboxamide
    
    CAS Number
    
    870070-55-6
    
    Molecular Formula
    
    C19H26N4O4S
    
    Molecular Weight
    
    406.5
    
    Purity
    
    99.14%
    
    Solubility
    
    insoluble in EtOH; insoluble in H2O; ≥20.35 mg/mL in DMSO
    
    Storage
    
    Store at -20°C
    
    SMILES
    
    CC1(CCN(CC1)C(=O)NC2=NC3=C(C=CC(=C3S2)N4CCOCC4)OC)O
    
    * For Research Use Only